S&P 500 slips on report Fed’s Waller leading race to replace Powell; tech shines
Insmed (NASDAQ:INSM), a $19.55 billion biopharmaceutical company whose shares are trading near their 52-week high of $106.83, reported that Chair and CEO William Lewis (JO:LEWJ), through the Katie Procter Dynasty Trust, sold a total of 6,830 shares of common stock on July 15, 2025, for approximately $699,220. The sales occurred in a price range of $101.71 to $103.32 per share.
According to a Form 4 filing with the Securities and Exchange Commission, the transactions were executed under a prearranged 10b5-1 trading plan.
On the same day, Lewis, via the Katie Procter Dynasty Trust, exercised options to acquire 6,830 shares of Insmed common stock at a price of $10.85, for a total value of $74,105.
Following these transactions, the Katie Procter Dynasty Trust indirectly holds 233,924 shares of Insmed. William Lewis also directly holds 303,911 shares and indirectly holds 50,500 shares through the William Lewis Family Legacy Trust.
In other recent news, Insmed Incorporated has reported significant developments that could impact investor interest. The company has successfully raised approximately $750 million through a public offering of 7,812,500 shares at $96.00 per share. These funds are earmarked for research and development, including projects involving brensocatib and the commercialization of ARIKAYCE. Additionally, Insmed announced plans for another public offering aimed at generating $650 million, with Goldman Sachs & Co (NYSE:GS). LLC and Leerink Partners as joint book-running managers.
Analysts have taken note of Insmed’s progress, particularly with its treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH). Mizuho Financial Group (NYSE:MFG) reiterated its Outperform rating, citing positive Phase 2b trial results and a potential "game-changer" status for TPIP. RBC Capital also raised its price target from $99 to $106, noting strong efficacy data and potential revenue projections of $2.2 billion by 2034 for TPIP. H.C. Wainwright increased its price target to $120 from $90, based on positive Phase 2A and 2B study results for TPIP. These developments suggest continued interest and potential growth opportunities for Insmed in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.